HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE
2013/07/30 by Tiffany N Caza, Tiffany Caza, David Fernández +22 · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Autophagy in Disease and Therapy #Cellular transport and secretion #Mitochondrial Function and Pathology
paper · pdf · doi:10.1136/annrheumdis-2013-203794
Abstract
OBJECTIVE: Accumulation of mitochondria underlies T-cell dysfunction in systemic lupus erythematosus (SLE). Mitochondrial turnover involves endosomal traffic regulated by HRES-1/Rab4, a small GTPase that is overexpressed in lupus T cells. Therefore, we investigated whether (1) HRES-1/Rab4 impacts mitochondrial homeostasis and (2) Rab geranylgeranyl transferase inhibitor 3-PEHPC blocks mitochondrial accumulation in T cells, autoimmunity and disease development in lupus-prone mice. METHODS: Mitochondria were evaluated in peripheral blood lymphocytes (PBL) of 38 SLE patients and 21 healthy controls and mouse models by flow cytometry, microscopy and western blot. MRL/lpr mice were treated with 125 μg/kg 3-PEHPC or 1 mg/kg rapamycin for 10 weeks, from 4 weeks of age. Disease was monitored by antinuclear antibody (ANA) production, proteinuria, and renal histology. RESULTS: Overexpression of HRES-1/Rab4 increased the mitochondrial mass of PBL (1.4-fold; p=0.019) and Jurkat cells (2-fold; p=0.000016) and depleted the mitophagy initiator protein Drp1 both in human (-49%; p=0.01) and mouse lymphocytes (-41%; p=0.03). Drp1 protein levels were profoundly diminished in PBL of SLE patients (-86±3%; p=0.012). T cells of 4-week-old MRL/lpr mice exhibited 4.7-fold over-expression of Rab4A (p=0.0002), the murine homologue of HRES-1/Rab4, and depletion of Drp1 that preceded the accumulation of mitochondria, ANA production and nephritis. 3-PEHPC increased Drp1 (p=0.03) and reduced mitochondrial mass in T cells (p=0.02) and diminished ANA production (p=0.021), proteinuria (p=0.00004), and nephritis scores of lupus-prone mice (p<0.001). CONCLUSIONS: These data reveal a pathogenic role for HRES-1/Rab4-mediated Drp1 depletion and identify endocytic control of mitophagy as a treatment target in SLE.
Cited by
- Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
- TLR7/9 and type I interferon signaling reprogram neutrophil NET responses and impair antibacterial defense in systemic lupus erythematosus
- Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
- Oxidative stress in the pathology and treatment of systemic lupus erythematosus. [europepmc]
- Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. [europepmc]
- mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. [europepmc]
- Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. [europepmc]
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). [europepmc]
- T cells and IL-17 in lupus nephritis. [europepmc]
- Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice. [europepmc]
- DNA methylation in systemic lupus erythematosus. [europepmc]
- Drp1-Dependent Mitochondrial Fission Plays Critical Roles in Physiological and Pathological Progresses in Mammals. [europepmc]
- Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation. [europepmc]
- Review: Metabolic Control of Immune System Activation in Rheumatic Diseases. [europepmc]
- Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus. [europepmc]
- Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. [europepmc]
- Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. [europepmc]
- REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). [europepmc]
- Targeting Autophagy to Overcome Human Diseases. [europepmc]
- Emerging views of mitophagy in immunity and autoimmune diseases. [europepmc]
- The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review. [europepmc]
- Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. [europepmc]
- Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells. [europepmc]
- The essential functions of mitochondrial dynamics in immune cells. [europepmc]
- IRGM1 links mitochondrial quality control to autoimmunity. [europepmc]
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 . [europepmc]
- Type I interferons affect the metabolic fitness of CD8 + T cells from patients with systemic lupus erythematosus. [europepmc]
- Targeting lysosomes in human disease: from basic research to clinical applications. [europepmc]
Related